Has the Market Fully Recognized Supernus Pharmaceuticals’ Strong Run and Growth Prospects in 2025?

Simply Wall St

Wed, December 17, 2025 at 7:13 PM EST 5 min read

If you are wondering whether Supernus Pharmaceuticals is still a smart buy after its recent run, or if the upside has already been priced in, you are not alone, and that is exactly what we are going to unpack.
The stock has climbed 5.7% over the last week, 8.2% over the past month, and is now up 33.9% year to date and 37.6% over the last year, building on an impressive 89.0% gain over five years.
Recent momentum has been driven by growing optimism around the company’s neurology focused portfolio and pipeline progress, alongside broader market interest in mid cap biotech names that can grow without relying solely on blockbuster launches. Together, these themes have nudged investors to reassess both the growth runway and the risk profile for Supernus.
On our framework, Supernus currently racks up a solid 5 out of 6 valuation score, suggesting it screens as undervalued on most metrics. In the sections that follow, we will walk through the main valuation approaches we use, before finishing with a more holistic way to think about what the market might be missing.

Supernus Pharmaceuticals delivered 37.6% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

A Discounted Cash Flow model estimates what a business is worth by projecting the cash it can generate in the future and then discounting those cash flows back to today, using a required rate of return.

For Supernus Pharmaceuticals, the latest twelve month free cash flow is about $71.1 million. Analysts provide detailed forecasts out to 2029, where free cash flow is expected to reach roughly $446.8 million. Beyond those analyst years, Simply Wall St extrapolates the trend so that by 2035 free cash flow is projected to be around $781.9 million, with growth slowing over time as the company matures.

When all these projected cash flows are discounted back to today in a 2 Stage Free Cash Flow to Equity model, the estimated intrinsic value works out to about $252.45 per share. At this level, the stock is trading at roughly an 80.7% discount to this DCF estimate. This indicates that the market price reflects significantly higher perceived risk or weaker growth expectations than those used in the model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Supernus Pharmaceuticals is undervalued by 80.7%. Track this in your watchlist or portfolio, or discover 914 more undervalued stocks based on cash flows.